Quick Takeaways
- URGN - UroGen Pharma Ltd. has 16 insiders with reported activity on this page.
- Net insider value flow over the last year: -$1,082,715.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 16 Insiders of UroGen Pharma Ltd.
- Symbol
- URGN on Nasdaq
- Location
- Ra'anana, Israel
What Changed
- Buy value: ; sell value: $1,082,715.
- Net share flow: -57,279.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$1,082,715.
Buys
$0
Shares: 0
Insiders: 0
Sells
$1,082,715
Shares: 57,279
Insiders: 3
Net
-$1,082,715
Shares: -57,279
Insiders: -3
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 14,852 | $0 | $292,436 | -$292,436 |
| 3-6 | 0 | 10,000 | $0 | $250,000 | -$250,000 |
| 6-9 | 0 | 27,265 | $0 | $502,236 | -$502,236 |
| 9-12 | 0 | 5,162 | $0 | $38,044 | -$38,044 |
UroGen Pharma Ltd. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ran Nussbaum | Director | $26,747,876 | Mixed | 21 Oct 2022 | ||
| Mark Schoenberg | Chief Medical Officer | $2,854,754 | -$725,315 | -20% | Filing P/S | 03 Feb 2026 |
| Jason Drew Smith | General Counsel | $1,094,527 | -$320,280 | -23% | Filing P/S | 31 Jan 2026 |
| Dong Kim | Chief Financial Officer | $493,809 | Mixed | 09 Sep 2024 | ||
| Molly Henderson | Chief Financial Officer | $94,516 | Mixed | 31 Jan 2022 | ||
| James A. Robinson Jr. | Director | $84,320 | Mixed | 26 Feb 2026 | ||
| Leana Wen | Director | $39,560 | Mixed | 26 Nov 2025 | ||
| Stuart Holden | Director | $39,560 | Mixed | 26 Nov 2025 | ||
| Daniel George Wildman | Director | $39,560 | Mixed | 26 Nov 2025 | ||
| Cynthia M. Butitta | Director | $39,560 | Mixed | 26 Nov 2025 | ||
| Chris Degnan | Chief Financial Officer | $38,418 | -$37,121 | -49% | Filing P/S | 31 Jan 2026 |
| Arie Belldegrun | Director | Mixed | 26 Aug 2025 | |||
| Elizabeth A. Barrett | Chief Executive Officer | Mixed | 31 Jan 2026 | |||
| Kathryn E. Falberg | Director | Mixed | 07 Jun 2021 | |||
| Shawn Tomasello | Director | Mixed | 07 Jun 2021 | |||
| Fred E. Cohen | Director | Mixed | 06 Aug 2024 |
Top shareholders of UroGen Pharma Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP |
13F
|
Company |
9.7%
|
4,543,895
|
$106,418,021 | — | 31 Dec 2025 | |
| Paradigm Biocapital Advisors LP |
13F
13D/G
|
Company |
9%
from 13D/G
|
4,473,648
|
$104,772,836 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5%
from 13D/G
|
2,601,009
|
$60,915,631 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
13D/G
|
Company |
5.4%
from 13D/G
|
2,562,901
|
$60,023,155 | — | 31 Dec 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
4.7%
|
2,199,652
|
$51,515,850 | — | 31 Dec 2025 | |
| TORONTO DOMINION BANK |
13D/G
|
The Toronto-Dominion Bank |
4.9%
|
2,302,334
|
$45,655,283 | -$17,612,530 | 31 Dec 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.7%
|
1,738,821
|
$40,723,188 | — | 31 Dec 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
3.1%
|
1,448,420
|
$33,921,996 | — | 31 Dec 2025 | |
| SG Americas Securities, LLC |
13F
|
Company |
2.9%
|
1,377,647
|
$32,264,000 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
2.9%
|
1,358,812
|
$31,823,425 | — | 31 Dec 2025 | |
| Soleus Capital Master Fund, L.P. |
13D/G
|
— |
4.7%
|
2,185,000
|
$31,114,400 | -$1,993,600 | 30 Jun 2025 | |
| MENORA MIVTACHIM HOLDINGS LTD. |
13F
13D/G
|
Company |
5%
from 13D/G
|
1,152,531
|
$26,992,276 | — | 31 Dec 2025 | |
| Ran Nussbaum |
3/4/5
|
Director |
—
class O/S missing
|
1,485,168
|
$26,747,876 | — | 21 Oct 2022 | |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND |
13F
|
Company |
2.4%
|
1,125,100
|
$26,349,842 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2%
|
962,624
|
$22,544,654 | — | 31 Dec 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
2%
|
941,378
|
$22,047,073 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.9%
|
875,487
|
$20,503,906 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.7%
|
807,421
|
$18,909,800 | — | 31 Dec 2025 | |
| FRONTIER CAPITAL MANAGEMENT CO LLC |
13F
|
Company |
1.7%
|
781,620
|
$18,305,546 | — | 31 Dec 2025 | |
| Migdal Insurance & Financial Holdings Ltd. |
13F
|
Company |
1.6%
|
770,909
|
$18,055,000 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.6%
|
737,757
|
$17,278,269 | — | 31 Dec 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
1.5%
|
718,354
|
$16,823,851 | — | 31 Dec 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.5%
|
717,347
|
$16,800,267 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.3%
|
618,952
|
$14,495,856 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.3%
|
616,606
|
$14,441,000 | — | 31 Dec 2025 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
2.8%
|
1,277,000
|
$13,740,520 | -$17,765,685 | 31 Mar 2025 | |
| J. Goldman & Co LP |
13F
|
Company |
1.1%
|
513,303
|
$12,021,556 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.1%
|
500,726
|
$11,727,003 | — | 31 Dec 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1.1%
|
500,000
|
$11,710,000 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1%
|
475,212
|
$11,129,464 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.98%
|
459,722
|
$10,766,689 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.94%
|
439,751
|
$10,298,969 | — | 31 Dec 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.93%
|
435,490
|
$10,199,176 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.78%
|
366,680
|
$8,587,645 | — | 31 Dec 2025 | |
| Monograph Capital Holdings Advisors, LLC |
13D/G
|
Monograph Capital Partners I, L.P. |
1.8%
|
838,615
|
$8,503,556 | $0 | 05 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.74%
|
350,000
|
$8,197,000 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.64%
|
302,601
|
$7,086,916 | — | 31 Dec 2025 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.6%
|
281,876
|
$6,601,536 | — | 31 Dec 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
0.57%
|
268,423
|
$6,286,467 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.52%
|
244,300
|
$5,721,506 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.51%
|
241,213
|
$5,649,208 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.51%
|
237,457
|
$5,561,243 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.5%
|
235,040
|
$5,504,637 | — | 31 Dec 2025 | |
| Atom Investors LP |
13F
|
Company |
0.5%
|
234,423
|
$5,490,187 | — | 31 Dec 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.46%
|
214,622
|
$5,026,447 | — | 31 Dec 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.36%
|
168,768
|
$3,952,547 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.35%
|
162,725
|
$3,811,020 | — | 31 Dec 2025 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.34%
|
161,924
|
$3,792,260 | — | 31 Dec 2025 | |
| Informed Momentum Co LLC |
13F
|
Company |
0.34%
|
160,412
|
$3,756,849 | — | 31 Dec 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.33%
|
153,413
|
$3,592,933 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for UroGen Pharma Ltd.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jason Drew Smith | URGN | Ordinary Shares | Sale | -12.7% | $147,262 | $19.69 | -7,479 | 51,326 | 03 Feb 2026 | Direct |
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -4.84% | $145,174 | $19.69 | -7,373 | 144,985 | 03 Feb 2026 | Direct |
| Elizabeth A. Barrett | URGN | Restricted Stock Units | Award | 153,195 | 153,195 | 31 Jan 2026 | Direct | |||
| Jason Drew Smith | URGN | Ordinary Shares | Options Exercise | 35.8% | 15,500 | 58,805 | 31 Jan 2026 | Direct | ||
| Jason Drew Smith | URGN | Restricted Stock Units | Award | 32,609 | 32,609 | 31 Jan 2026 | Direct | |||
| Jason Drew Smith | URGN | Restricted Stock Units | Options Exercise | -100% | -15,500 | 0 | 31 Jan 2026 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Options Exercise | 9.59% | 13,333 | 152,358 | 31 Jan 2026 | Direct | ||
| Mark Schoenberg | URGN | Restricted Stock Units | Award | 20,000 | 20,000 | 31 Jan 2026 | Direct | |||
| Mark Schoenberg | URGN | Restricted Stock Units | Options Exercise | -100% | -13,333 | 0 | 31 Jan 2026 | Direct | ||
| Chris Degnan | URGN | Restricted Stock Units | Award | 32,609 | 32,609 | 31 Jan 2026 | Direct | |||
| Stuart Holden | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Stuart Holden | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Cynthia M. Butitta | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Cynthia M. Butitta | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| James A. Robinson Jr. | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| James A. Robinson Jr. | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Leana Wen | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Leana Wen | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Daniel George Wildman | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Daniel George Wildman | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -6.71% | $250,000 | $25.00 | -10,000 | 139,025 | 19 Nov 2025 | Direct |
| Chris Degnan | URGN | Ordinary Shares | Sale | -49.1% | $37,121 | $16.85 | -2,203 | 2,280 | 08 Oct 2025 | Direct |
| Chris Degnan | URGN | Ordinary Shares | Options Exercise | 4,483 | 4,483 | 08 Oct 2025 | Direct | |||
| Chris Degnan | URGN | Restricted Stock Units | Options Exercise | -33.3% | -4,483 | 8,967 | 08 Oct 2025 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -0.58% | $16,645 | $19.11 | -871 | 149,025 | 08 Sep 2025 | Direct |
| Jason Drew Smith | URGN | Ordinary Shares | Sale | -3.39% | $29,047 | $19.11 | -1,520 | 43,305 | 08 Sep 2025 | Direct |
| Mark Schoenberg | URGN | Ordinary Shares | Options Exercise | 1.12% | 1,667 | 149,896 | 07 Sep 2025 | Direct | ||
| Mark Schoenberg | URGN | Restricted Stock Units | Options Exercise | -50% | -1,667 | 1,667 | 07 Sep 2025 | Direct | ||
| Jason Drew Smith | URGN | Ordinary Shares | Options Exercise | 8.03% | 3,333 | 44,825 | 07 Sep 2025 | Direct | ||
| Jason Drew Smith | URGN | Restricted Stock Units | Options Exercise | -50% | -3,333 | 3,334 | 07 Sep 2025 | Direct | ||
| Daniel George Wildman | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct | |||
| Daniel George Wildman | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 26 Aug 2025 | Direct | |||
| James A. Robinson Jr. | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct | |||
| James A. Robinson Jr. | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 26 Aug 2025 | Direct | |||
| Stuart Holden | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct | |||
| Stuart Holden | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 26 Aug 2025 | Direct | |||
| Cynthia M. Butitta | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct | |||
| Cynthia M. Butitta | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 26 Aug 2025 | Direct | |||
| Leana Wen | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct | |||
| Leana Wen | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 26 Aug 2025 | Direct | |||
| Arie Belldegrun | URGN | Stock Option (right ot buy) | Award | 20,000 | 20,000 | 26 Aug 2025 | Direct | |||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -6.32% | $176,900 | $17.69 | -10,000 | 148,229 | 11 Aug 2025 | Direct |
| Elizabeth A. Barrett | URGN | Performance Stock Units | Award | 87,615 | 87,615 | 28 Jul 2025 | Direct | |||
| Jason Drew Smith | URGN | Ordinary Shares | Sale | -15.4% | $143,971 | $19.14 | -7,522 | 41,492 | 28 Jul 2025 | Direct |
| Jason Drew Smith | URGN | Ordinary Shares | Options Exercise | 50.8% | 16,500 | 49,014 | 28 Jul 2025 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -3.15% | $98,552 | $19.14 | -5,149 | 158,229 | 28 Jul 2025 | Direct |
| Mark Schoenberg | URGN | Ordinary Shares | Options Exercise | 6.52% | 10,000 | 163,378 | 28 Jul 2025 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -3.26% | $38,044 | $7.37 | -5,162 | 153,378 | 09 Jun 2025 | Direct |
| Mark Schoenberg | URGN | Ordinary Shares | Options Exercise | 6.73% | 10,000 | 158,540 | 08 Jun 2025 | Direct | ||
| Mark Schoenberg | URGN | Restricted Stock Units | Options Exercise | -50% | -10,000 | 10,000 | 08 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.